Wuhan Healthgen Biotechnology (SHSE:688765) Total Liabilities: ¥772.63 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
19 GF Score
Price ¥55.00
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology Total Liabilities?

Wuhan Healthgen Biotechnology SHSE:688765 +5.40% 19 Total Liabilities is ¥772.63 Mil as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

Wuhan Healthgen Biotechnology's Total Liabilities for the quarter that ended in Mar. 2026 was ¥772.63 Mil.

Wuhan Healthgen Biotechnology's quarterly Total Liabilities declined from Sep. 2025 (¥967.08 Mil) to Dec. 2025 (¥805.00 Mil) and declined from Dec. 2025 (¥805.00 Mil) to Mar. 2026 (¥772.63 Mil).

Wuhan Healthgen Biotechnology's annual Total Liabilities increased from Dec. 2023 (¥230.58 Mil) to Dec. 2024 (¥460.46 Mil) and increased from Dec. 2024 (¥460.46 Mil) to Dec. 2025 (¥805.00 Mil).

Wuhan Healthgen Biotechnology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology Total Liabilities Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 133.81 207.41 230.58 460.46 805.00

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 655.30 786.35 967.08 805.00 772.63
SHSE:688765
19GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wuhan Healthgen Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=453.597+(313.269+38.131
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=805.00

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3702.888-2897.891
=805.00

Wuhan Healthgen Biotechnology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=566.414+(168.706+37.509
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=772.63

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=3641.232-2868.604
=772.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ¥772.63 Mil mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a Total Liabilities of ¥772.63 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's Total Liabilities too high?
Wuhan Healthgen Biotechnology's current Total Liabilities is ¥772.63 Mil. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Total Liabilities compare to ZTS and UTHR?
Wuhan Healthgen Biotechnology's Total Liabilities of ¥772.63 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wuhan Healthgen Biotechnology and its competitors. Wuhan Healthgen Biotechnology's current Total Liabilities is ¥772.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Total Liabilities of ¥772.63 Mil. The current Total Liabilities is ¥772.63 Mil. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Total Liabilities is ¥772.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
19GF Score

Get the complete analysis for SHSE:688765

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥55.00
Price